Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Short-term (Operating) Activity Ratios 

Microsoft Excel

Short-term Activity Ratios (Summary)

Abbott Laboratories, short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Turnover Ratios
Inventory turnover 3.02 2.74 3.10 3.59 2.99
Receivables turnover 6.06 6.11 7.02 6.64 5.40
Payables turnover 4.46 4.19 4.15 4.21 3.80
Working capital turnover 4.42 4.54 4.48 3.87 4.06
Average No. Days
Average inventory processing period 121 133 118 102 122
Add: Average receivable collection period 60 60 52 55 68
Operating cycle 181 193 170 157 190
Less: Average payables payment period 82 87 88 87 96
Cash conversion cycle 99 106 82 70 94

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data indicates several notable trends in the company's operational efficiency over the analyzed period.

Inventory Turnover
The inventory turnover ratio exhibits fluctuations, increasing from 2.99 in 2020 to a peak of 3.59 in 2021, followed by a decline to 2.74 in 2023 before a partial recovery to 3.02 in 2024. This suggests variability in the efficiency with which inventory is managed and sold.
Receivables Turnover
The receivables turnover ratio shows an upward trend from 5.4 in 2020, reaching 7.02 in 2022, indicating improved collection efficiency. However, it then slightly declines to around 6.06 by 2024, suggesting some easing in receivables management efficiency.
Payables Turnover
Payables turnover ratio gradually increases from 3.8 in 2020 to 4.46 in 2024, indicating the company is paying its suppliers at a somewhat faster rate over time.
Working Capital Turnover
Working capital turnover remains relatively stable with minor variations, beginning at 4.06 in 2020, dipping slightly in 2021, then increasing to a peak of 4.54 in 2023 before a subtle decrease in 2024. This reflects consistent effectiveness in utilizing working capital for generating sales.
Average Inventory Processing Period
The period for inventory processing decreases notably from 122 days in 2020 to 102 days in 2021, implying faster inventory movement. However, it then lengthens again to 133 days in 2023 before improving to 121 days in 2024, mirroring the inventory turnover pattern.
Average Receivable Collection Period
The average collection period shortens significantly from 68 days in 2020 to 52 days in 2022, indicating better receivables management. It stabilizes at 60 days in 2023 and 2024, suggesting some slowing in collection speed.
Operating Cycle
The operating cycle decreases sharply from 190 days in 2020 to 157 days in 2021, indicating improved operational efficiency, but then it lengthens to 193 days in 2023 before reducing to 181 days in 2024. This variability highlights fluctuating overall operational timing.
Average Payables Payment Period
This period decreases from 96 days in 2020 to 82 days in 2024, indicating the company is paying suppliers more promptly over time, which aligns with the increasing payables turnover ratio.
Cash Conversion Cycle
The cash conversion cycle follows a downward trend from 94 days in 2020 to 70 days in 2021, reflecting improved liquidity and operational efficiency. However, it then expands to 106 days in 2023, indicating a slowdown, before a slight improvement to 99 days in 2024.

Overall, the data reveals a pattern of initial improvements in operational efficiency and cash flow management during the earlier years, followed by some regression or volatility in the subsequent periods. Inventory and receivables management show fluctuations impacting the operating and cash conversion cycles, while payables are being settled progressively faster, which may affect liquidity timing. These trends highlight the importance of continuous focus on inventory and receivables processes to optimize operational efficiency and cash flow dynamics.


Turnover Ratios


Average No. Days


Inventory Turnover

Abbott Laboratories, inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets 18,706 17,975 19,142 18,537 15,003
Inventories 6,194 6,570 6,173 5,157 5,012
Short-term Activity Ratio
Inventory turnover1 3.02 2.74 3.10 3.59 2.99
Benchmarks
Inventory Turnover, Competitors2
CVS Health Corp. 17.75 16.83 14.05 13.52 11.88
Intuitive Surgical Inc. 1.83 1.96 2.27 2.98 2.49
Medtronic PLC 2.15 2.03 2.20 2.43 2.23
Inventory Turnover, Sector
Health Care Equipment & Services 24.05 22.52 20.37 20.15 17.40
Inventory Turnover, Industry
Health Care 9.50 9.18 9.22 9.17 8.17

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Inventory turnover = Cost of products sold, excluding amortization of intangible assets ÷ Inventories
= 18,706 ÷ 6,194 = 3.02

2 Click competitor name to see calculations.


The financial data indicates significant fluctuations in key metrics related to the cost of products sold and inventory management over the five-year period.

Cost of products sold, excluding amortization of intangible assets
This metric increased notably from 15,003 million US dollars in 2020 to 18,537 million in 2021, representing a substantial rise. It continued to grow slightly to 19,142 million in 2022 but then declined to 17,975 million in 2023. There was a modest rebound to 18,706 million in 2024, though the figure remained below the 2022 peak.
Inventories
Inventory levels showed a steady upward trend from 5,012 million US dollars in 2020, increasing each year until peaking at 6,570 million in 2023. However, inventories decreased in 2024 to 6,194 million, indicating a partial drawdown or improved inventory management in the latest period.
Inventory turnover ratio
This ratio, which measures how efficiently inventory is managed and sold, fluctuated over the period. Starting at 2.99 in 2020, it rose to 3.59 in 2021, indicating improved efficiency. However, it dropped in 2022 and 2023 to 3.1 and 2.74 respectively, suggesting slower inventory movement. By 2024, the turnover ratio increased again to 3.02, pointing to a recovery in inventory efficiency.

Overall, the cost of products sold experienced a growth peak around 2022 followed by a decline and subsequent partial recovery. Inventory amounts rose consistently until 2023, before declining in 2024, while inventory turnover demonstrated volatility, with cycles of improvement and reduction. These trends suggest varying operational dynamics affecting cost control and inventory management during the period.


Receivables Turnover

Abbott Laboratories, receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Net sales 41,950 40,109 43,653 43,075 34,608
Trade receivables, less allowances 6,925 6,565 6,218 6,487 6,414
Short-term Activity Ratio
Receivables turnover1 6.06 6.11 7.02 6.64 5.40
Benchmarks
Receivables Turnover, Competitors2
CVS Health Corp. 10.16 10.12 11.79 11.91 12.32
Elevance Health Inc. 18.00 18.08 18.81 20.66 19.72
Intuitive Surgical Inc. 6.82 6.30 6.60 7.30 6.75
Medtronic PLC 5.28 5.21 5.71 5.51 6.22
UnitedHealth Group Inc. 17.66 17.27 18.22 20.07 19.86
Receivables Turnover, Sector
Health Care Equipment & Services 12.24 12.11 13.26 13.54 13.48
Receivables Turnover, Industry
Health Care 8.42 8.15 8.84 8.65 8.64

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Receivables turnover = Net sales ÷ Trade receivables, less allowances
= 41,950 ÷ 6,925 = 6.06

2 Click competitor name to see calculations.


The financial data over the five-year period reveals notable trends in revenue, trade receivables, and receivables turnover for the analyzed company.

Net Sales
Net sales grew significantly from US$34,608 million in 2020 to US$43,075 million in 2021, representing a strong increase. From 2021 to 2022, sales showed marginal growth, reaching US$43,653 million. However, sales declined in 2023 to US$40,109 million, followed by a moderate recovery to US$41,950 million in 2024. This indicates volatility in sales performance, with a peak in 2021 followed by fluctuations in subsequent years.
Trade Receivables, Less Allowances
Trade receivables remained relatively stable throughout the period with a slight upward trend. Starting at US$6,414 million in 2020, receivables exhibited minor fluctuations and ended higher at US$6,925 million in 2024. This suggests consistent credit sales management with a gradual increase, possibly reflecting higher sales volumes or relaxed collection policies over time.
Receivables Turnover Ratio
The receivables turnover ratio improved notably from 5.4 in 2020 to a peak of 7.02 in 2022, indicating faster collection of receivables and enhanced efficiency in accounts receivable management. However, the ratio declined in 2023 and 2024 to approximately 6.11 and 6.06 respectively, signaling a slowdown in the collection process compared to the peak year. Despite this decrease, turnover remains above the 2020 level.

Overall, the analysis depicts a company experiencing initial strong revenue growth, followed by some variability in sales performance. Trade receivables showed a modest increase, while receivables turnover reflected improvements in collection efficiency through 2022, with a slight decline in subsequent years. These trends highlight areas of strength in credit management alongside challenges in sustaining sales momentum and receivables collection pace after 2022.


Payables Turnover

Abbott Laboratories, payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets 18,706 17,975 19,142 18,537 15,003
Trade accounts payable 4,195 4,295 4,607 4,408 3,946
Short-term Activity Ratio
Payables turnover1 4.46 4.19 4.15 4.21 3.80
Benchmarks
Payables Turnover, Competitors2
CVS Health Corp. 20.22 20.36 18.07 19.14 19.72
Elevance Health Inc. 8.10 7.72 7.47 7.59 7.75
Intuitive Surgical Inc. 14.05 12.69 13.78 14.45 18.35
Medtronic PLC 4.65 4.03 4.46 4.98 4.72
UnitedHealth Group Inc. 7.72 7.47 7.26 7.63 7.29
Payables Turnover, Sector
Health Care Equipment & Services 10.26 9.93 9.42 9.80 9.78
Payables Turnover, Industry
Health Care 8.12 7.96 7.50 7.61 7.48

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Payables turnover = Cost of products sold, excluding amortization of intangible assets ÷ Trade accounts payable
= 18,706 ÷ 4,195 = 4.46

2 Click competitor name to see calculations.


Cost of Products Sold, Excluding Amortization of Intangible Assets
The cost of products sold generally increased over the period presented. Starting at 15,003 million US dollars in 2020, the cost rose significantly to 18,537 million in 2021 and continued increasing to 19,142 million in 2022. However, in 2023, there was a notable decrease to 17,975 million, before rising again to 18,706 million in 2024. This pattern suggests some volatility but an overall upward trend in production or procurement costs over the five-year span.
Trade Accounts Payable
The value of trade accounts payable exhibited a gradual increase from 3,946 million US dollars in 2020 to 4,607 million in 2022. After reaching this peak, the payable balance declined to 4,295 million in 2023 and further decreased to 4,195 million in 2024. This trend indicates a moderate increase in short-term liabilities related to suppliers up to 2022, followed by a reduction in subsequent years.
Payables Turnover Ratio
The payables turnover ratio improved steadily from 3.8 in 2020 to 4.21 in 2021, indicating faster payment to suppliers or improved efficiency in managing payables. The ratio slightly decreased to 4.15 in 2022 but rose again to 4.19 in 2023 and further to 4.46 in 2024, representing the highest turnover in the period. Overall, this ratio reflects effective management of payables and possibly favorable supplier terms or cash flow improvements over time.

Working Capital Turnover

Abbott Laboratories, working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Current assets 23,656 22,670 25,224 24,239 20,441
Less: Current liabilities 14,157 13,841 15,489 13,105 11,907
Working capital 9,499 8,829 9,735 11,134 8,534
 
Net sales 41,950 40,109 43,653 43,075 34,608
Short-term Activity Ratio
Working capital turnover1 4.42 4.54 4.48 3.87 4.06
Benchmarks
Working Capital Turnover, Competitors2
CVS Health Corp.
Elevance Health Inc. 7.85 7.83 8.37 7.23 6.39
Intuitive Surgical Inc. 1.56 1.14 1.29 1.22 0.77
Medtronic PLC 2.90 2.47 2.97 2.15 2.48
UnitedHealth Group Inc.
Working Capital Turnover, Sector
Health Care Equipment & Services 95.28 67.67 50.71 35.48 39.06
Working Capital Turnover, Industry
Health Care 19.80 16.59 15.34 11.93 11.78

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Working capital turnover = Net sales ÷ Working capital
= 41,950 ÷ 9,499 = 4.42

2 Click competitor name to see calculations.


Working Capital
The working capital shows a fluctuating trend over the five-year period. It initially increased from 8,534 million US dollars in 2020 to a peak of 11,134 million US dollars in 2021. Subsequently, it declined to 9,735 million in 2022 and further to 8,829 million in 2023. In 2024, there was a slight recovery to 9,499 million US dollars.
Net Sales
Net sales experienced overall growth with some variation between years. The figure rose significantly from 34,608 million US dollars in 2020 to 43,075 million in 2021. It then showed a minor increase to 43,653 million in 2022. However, net sales dropped in 2023 to 40,109 million before recovering to 41,950 million US dollars in 2024.
Working Capital Turnover
The working capital turnover ratio, which measures the efficiency with which working capital is used to generate sales, was fairly stable with moderate fluctuations. It declined from 4.06 in 2020 to 3.87 in 2021, indicating slightly less efficiency despite higher sales. Afterward, the ratio improved, rising to 4.48 in 2022, then gradually increased to 4.54 in 2023, before a small decrease to 4.42 in 2024.
Overall Analysis
The financial data indicates that the company faced variability in both working capital and net sales over this period. The peak in working capital in 2021 aligns with the highest net sales, though efficiency in using working capital (turnover ratio) was lower that year. The following years showed some correction in working capital levels combined with a decline and partial recovery in sales. The improvement in the working capital turnover ratio after 2021 suggests enhanced operational efficiency in managing current assets to generate sales. The slight dip in 2024 warrants attention but remains within a stable range.

Average Inventory Processing Period

Abbott Laboratories, average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Inventory turnover 3.02 2.74 3.10 3.59 2.99
Short-term Activity Ratio (no. days)
Average inventory processing period1 121 133 118 102 122
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
CVS Health Corp. 21 22 26 27 31
Intuitive Surgical Inc. 200 186 161 122 147
Medtronic PLC 170 180 166 150 164
Average Inventory Processing Period, Sector
Health Care Equipment & Services 15 16 18 18 21
Average Inventory Processing Period, Industry
Health Care 38 40 40 40 45

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.02 = 121

2 Click competitor name to see calculations.


Inventory Turnover
The inventory turnover ratio exhibited fluctuation throughout the observed period. It increased from 2.99 in 2020 to a peak of 3.59 in 2021, indicating an improvement in the frequency of inventory sales relative to average inventory held. However, this was followed by a decline to 3.1 in 2022 and further dropped to 2.74 in 2023, signaling a decrease in operational efficiency or potentially increased inventory levels. By 2024, the ratio recovered somewhat to 3.02, suggesting a partial return to earlier turnover efficiency.
Average Inventory Processing Period
The average inventory processing period moved inversely to the inventory turnover ratio, as is typical. It started at 122 days in 2020 and decreased notably to 102 days in 2021, reflecting faster inventory turnover and possibly improved inventory management. Subsequently, the processing period increased to 118 days in 2022 and peaked at 133 days in 2023, indicating slower movement of inventory or extended holding times. In 2024, there was a reduction to 121 days, hinting at a slight improvement in the speed of inventory processing compared to the previous year.
Overall Trends and Insights
Overall, the data reveals an initial improvement in inventory management efficiency in 2021, characterized by higher turnover and shorter processing periods. After this peak, both metrics reflect a decline in operational efficiency through 2023, with turnover decreasing and inventory holding periods lengthening. The partial recovery noted in 2024 may indicate strategic adjustments to inventory control or market conditions improving. Continuous monitoring is advised to ensure sustained efficiency in inventory management.

Average Receivable Collection Period

Abbott Laboratories, average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Receivables turnover 6.06 6.11 7.02 6.64 5.40
Short-term Activity Ratio (no. days)
Average receivable collection period1 60 60 52 55 68
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
CVS Health Corp. 36 36 31 31 30
Elevance Health Inc. 20 20 19 18 19
Intuitive Surgical Inc. 54 58 55 50 54
Medtronic PLC 69 70 64 66 59
UnitedHealth Group Inc. 21 21 20 18 18
Average Receivable Collection Period, Sector
Health Care Equipment & Services 30 30 28 27 27
Average Receivable Collection Period, Industry
Health Care 43 45 41 42 42

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.06 = 60

2 Click competitor name to see calculations.


Receivables Turnover
The receivables turnover ratio exhibited an overall increasing trend from 5.4 in 2020 to a peak of 7.02 in 2022, indicating an improvement in the efficiency of collections during this period. However, this upward momentum slowed down and slightly reversed in 2023 and 2024, declining to 6.11 and 6.06 respectively, suggesting a moderate reduction in the pace at which receivables are converted into cash.
Average Receivable Collection Period
The average collection period decreased from 68 days in 2020 to a minimum of 52 days by the end of 2022, reflecting faster receivable turnover and possibly more effective credit policies or collection efforts during these years. Starting in 2023, the trend reversed slightly, with the collection period increasing back to 60 days in both 2023 and 2024, implying a deceleration in collection efficiency compared to the prior two years.
Summary of Trends
The data reveals that between 2020 and 2022, the company improved its receivables management, turning over receivables more frequently and reducing the time customers took to pay. However, from 2023 onwards, there was a modest decline in these efficiencies, with turnover ratios decreasing and collection periods lengthening. This suggests that while the company maintained relatively strong receivables performance, there are signs of a slight weakening in collection effectiveness during the most recent two years.

Operating Cycle

Abbott Laboratories, operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Average inventory processing period 121 133 118 102 122
Average receivable collection period 60 60 52 55 68
Short-term Activity Ratio
Operating cycle1 181 193 170 157 190
Benchmarks
Operating Cycle, Competitors2
CVS Health Corp. 57 58 57 58 61
Intuitive Surgical Inc. 254 244 216 172 201
Medtronic PLC 239 250 230 216 223
Operating Cycle, Sector
Health Care Equipment & Services 45 46 46 45 48
Operating Cycle, Industry
Health Care 81 85 81 82 87

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 121 + 60 = 181

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period showed a fluctuating trend over the analyzed years. It initially decreased from 122 days in 2020 to 102 days in 2021, indicating a quicker turnover of inventory during that period. However, this trend reversed in the following years, rising to 118 days in 2022 and further increasing to 133 days in 2023. By 2024, the figure declined again to 121 days, nearly returning to the level observed in 2020. Overall, the period demonstrates variability with no steady long-term reduction or increase.
Average Receivable Collection Period
The average receivable collection period displayed a generally decreasing trend from 2020 to 2022, going from 68 days to 52 days, which suggests improving efficiency in collecting receivables over that timeframe. After 2022, the period increased to 60 days in 2023 and remained stable in 2024. This pattern may indicate initial improvements in credit management followed by a stabilization or slight relaxation of collection efforts in the most recent years.
Operating Cycle
The operating cycle experienced a downward shift from 190 days in 2020 to 157 days in 2021, reflecting a more efficient overall operating process. Following this improvement, the operating cycle increased again to 170 days in 2022 and further rose to 193 days in 2023, surpassing the initial 2020 level. In 2024, the operating cycle shortened somewhat to 181 days, though it remained higher than the figures from 2020 and 2021. This illustrates a period of improvement followed by increasing operational duration and a slight recent recovery towards efficiency.
Overall Insights
The financial periods indicate a fluctuating scenario regarding inventory management, receivables collection, and the overall operating cycle. Early periods suggested operational efficiency gains, but subsequent years revealed a reversal with longer periods to process inventory and complete the operating cycle. Receivable collection improved initially but stabilized at a somewhat higher duration after 2022. These trends highlight challenges in maintaining continuous improvement in working capital management and operational efficiency.

Average Payables Payment Period

Abbott Laboratories, average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Payables turnover 4.46 4.19 4.15 4.21 3.80
Short-term Activity Ratio (no. days)
Average payables payment period1 82 87 88 87 96
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
CVS Health Corp. 18 18 20 19 19
Elevance Health Inc. 45 47 49 48 47
Intuitive Surgical Inc. 26 29 26 25 20
Medtronic PLC 78 91 82 73 77
UnitedHealth Group Inc. 47 49 50 48 50
Average Payables Payment Period, Sector
Health Care Equipment & Services 36 37 39 37 37
Average Payables Payment Period, Industry
Health Care 45 46 49 48 49

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 4.46 = 82

2 Click competitor name to see calculations.


Payables Turnover
The payables turnover ratio shows a generally positive trend over the observed periods. Beginning at 3.8 in 2020, the ratio increased to 4.21 in 2021. Although there was a slight decrease to 4.15 in 2022, it recovered to 4.19 in 2023 and further improved to 4.46 in 2024. This upward tendency suggests a progressively more efficient management of accounts payable, indicating that the company is accelerating its payments to suppliers or better managing its payment obligations.
Average Payables Payment Period
The average payables payment period reflects a decreasing trend over the years, starting at 96 days in 2020 and declining consistently to 82 days by 2024. This decline corresponds inversely with the payables turnover ratio, reinforcing the interpretation that the company is shortening the time it takes to settle its payables. This movement may reflect improved liquidity management or changes in supplier payment terms.
Overall Insights
The combination of an increasing payables turnover ratio and a decreasing average payables payment period over the five-year span indicates enhanced efficiency in managing payables. These trends could imply stronger supplier relationships or more stringent internal controls on cash outflows. However, a more rapid payment cycle might impact the company’s short-term cash flow and working capital management, which should be monitored alongside other financial indicators.

Cash Conversion Cycle

Abbott Laboratories, cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Average inventory processing period 121 133 118 102 122
Average receivable collection period 60 60 52 55 68
Average payables payment period 82 87 88 87 96
Short-term Activity Ratio
Cash conversion cycle1 99 106 82 70 94
Benchmarks
Cash Conversion Cycle, Competitors2
CVS Health Corp. 39 40 37 39 42
Intuitive Surgical Inc. 228 215 190 147 181
Medtronic PLC 161 159 148 143 146
Cash Conversion Cycle, Sector
Health Care Equipment & Services 9 9 7 8 11
Cash Conversion Cycle, Industry
Health Care 36 39 32 34 38

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 121 + 6082 = 99

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period displays some fluctuation over the five-year span. Starting at 122 days in 2020, it decreased notably to 102 days in 2021. However, it rose again to 118 days in 2022, increased further to a peak of 133 days in 2023, before declining to 121 days in 2024. This pattern suggests varying efficiency in inventory management, with a general increase in days tied up in inventory towards the later years.
Average Receivable Collection Period
The receivable collection period saw a steady improvement from 68 days in 2020 to 55 days in 2021 and then a modest improvement to 52 days in 2022. However, this improvement reversed in 2023, increasing to 60 days, a level that remained stable into 2024. This indicates an initial enhancement in the efficiency of receivables collection, followed by a period where collection speed slowed down and stabilized at a higher level.
Average Payables Payment Period
There is a gradual reduction in the average payables payment period across the years. Beginning at 96 days in 2020, it decreased to 87 days by 2021 and remained relatively stable around 87–88 days through 2022 and 2023, before dropping further to 82 days in 2024. This suggests a trend towards quicker payments to suppliers over the timeframe analyzed.
Cash Conversion Cycle
The cash conversion cycle experienced notable variability. Starting at 94 days in 2020, it improved markedly to 70 days in 2021, indicating better overall working capital management. However, it then lengthened to 82 days in 2022, further extended to 106 days in 2023, before decreasing somewhat to 99 days in 2024. Despite initial gains, the overall trend after 2021 shows a lengthening cash conversion cycle, implying more days where cash is tied up in operations.
Overall Assessment
The analysis reveals that despite efforts to improve receivables collection and expedite payments to suppliers, the increasing inventory processing period contributes to an elongated cash conversion cycle after 2021. This suggests that inventory management remains an area requiring attention to enhance liquidity and reduce the time cash is committed to operational processes. The recent decline in the cash conversion cycle in 2024 may indicate preliminary corrective actions or improvements, but the cycle remains longer than the low point achieved in 2021.